Monday, February 26, 2018

XLRN

Acceleron Pharma upgraded to Overweight with a $52 (21% upside) price target at JPMorgan.



Submitted February 26, 2018 at 10:32AM by SueBid http://ift.tt/2Cm7V6y
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)